Navigation Links
Ossur -- leading orthopedic pioneer - expands network to Asia
Date:10/5/2007

October 5, 2007 - Shanghai Ossur, a leading provider of non-invasive orthopaedic products and services, today announced the inauguration of its Asia Pacific operations in Shanghai, China. Ossur, renowned for its pioneering work in lower-limb prosthetics and a comprehensive range of braces and supports, established its China office as the regional headquarters catering to customers not just in China but across Asia including Japan, South Korea and Australia.

The total prosthetic market in Asia is USD260 million of which USD56 million is in components and devices. In China, we estimate the total market being USD35 million. In Asia, lifestyle diseases such as diabetes and other arterial diseases that lead to amputation are showing a significant rise as compared to Western countries. In addition, workplace accidents or trauma have also led to increased lower-limb amputations. There are approximately 2.2 million amputees in China with over 100,000 new amputees expected each year . It is estimated that 70% of amputations are related to some form of trauma .

China will become the third largest healthcare market by the year 2020, said Arni Alvar Arason, president Ossur Asia. China has all the key elements that make it the ideal choice for our regional headquarters investment, distribution, supply chain network, proximity to key Asian markets - not to mention a growing patient base requiring prosthetics. Ossur is already looking into setting up manufacturing and R&D capabilities in the very near future. Currently, Ossur provides prosthetics and components to about 15,000 Chinese patients who use them on a daily basis. When Ossur begins to supply and distribute braces and supports from its Asia office, this category is expected to grow significantly.

Establishing an office in China to meet market demand in this region is part of Ossurs 2010 company vision: to focus more on Asian markets. Presiding at the inauguration, president & CEO Jon Sigurdsson stressed the importance of building Ossur in key growth areas. What inspires Ossurs growth is recognizing the needs of our customers and meeting them, whether it is in products, technology, education or in the supply chain. We see China as an important growth market for us.

Ossur launched a new Bionic Technology platform of products in 2005, transitioning the company towards sophisticated high-end electronics and software development. Microprocessors and the development of critical electronic parts are becoming an increasingly important part of the prosthetic development phase. The proximity to a strong patient population as well as an electronics industry in Asia, not to mention the growing orthopaedic and prosthetic medical community in Shanghai, makes China a good location.

Ossur is not only about products. Ossur provides extensive educational and clinical support programs through the Ossur Academy, a global initiative to assist orthopaedic professionals and prosthetists in delivering the best possible experience and outcome for their patients. Ossur currently sponsors university level courses to several universities in the region. Based on growing patient demand, the Orthopaedic and Prosthetic industry will greatly benefit from Ossurs education and technical support programs in China and Asia while, at the same time, helping to develop the O&P industry in the region.

Prosthetics in Japan, South Korea and Australia are expected to be core growth areas over the next 2-3 years. In China, the bracing and support market will continue to be developed through its network of local partners and distributors in the region. Arason added, our philosophy is to continue to enhance and develop quality solutions and to be the leader in this field. Ossur is not about fitting legs. Ossur is about making a difference and bringing people back to the same standard of living that they enjoyed before. For our patients, we believe in a life without limitations. That is our commitment.


'/>"/>

Contact: Edda Geirsdottir
egeirsdottir@ossur.com
354-664-1055
Ossur
Source:Eurekalert

Related biology news :

1. Enzyme allows B cells to resist death, leading to leukemia
2. Scientists document complex genomic events leading to the birth of new genes
3. Genetic links could unlock clues to leading cause of blindness
4. Leading scientists rank endangered dolphins, porpoises most in need of immediate action
5. Why do aneurysms form? New studies suggest leading role for white blood cells
6. Leading lampreys to slaughter: Pheromone for scourge of Great Lakes identified
7. Jefferson scientists identify gene defect leading to abnormal skin development and cancer
8. ORNL leading effort to help harness power of Shewanella
9. Leading reason for corneal transplants comes into focus
10. Twin studies reveal genetic components leading to cardiac and kidney disease
11. Climate change could trigger boom and bust population cycles leading to extinction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... SARASOTA, FL (PRWEB) , ... ... ... Inc. (RPS®) today announces publication of a United States multicenter, prospective clinical ... single use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
Breaking Biology Technology: